NASDAQ:GTBP GT Biopharma Q2 2024 Earnings Report $0.75 +0.04 (+5.64%) As of 11:03 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast GT Biopharma EPS ResultsActual EPS-$2.24Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AGT Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGT Biopharma Announcement DetailsQuarterQ2 2024Date8/14/2024TimeN/AConference Call DateWednesday, August 14, 2024Conference Call Time7:00AM ETUpcoming EarningsGT Biopharma's Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) GT Biopharma Earnings HeadlinesGT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas SummitOctober 6 at 12:08 PM | markets.businessinsider.comGT Biopharma Alters Preferred Stockholder RightsSeptember 26, 2025 | msn.com⚠️ Last Chance: 3 Consumer Defensive Stocks Poised to Dominate in Tariff WarThe Fed’s playing guessing games. Stocks are sinking because of the Trade War. Retail investors are panicking. But smart money? They’re quietly buying 3 consumer defensive stocks.October 7 at 2:00 AM | StockEarnings (Ad)GT Biopharma Waives Series L Stock Redemption RightsSeptember 23, 2025 | tipranks.comGT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | markets.businessinsider.comGT Biopharma IncAugust 28, 2025 | cnn.comSee More GT Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like GT Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GT Biopharma and other key companies, straight to your email. Email Address About GT BiopharmaGT Biopharma (NASDAQ:GTBP) is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events. The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS). Beyond GTB-3550, GT Biopharma is advancing a pipeline of preclinical TriKE constructs aimed at both hematologic and solid tumors, as well as exploring applications in infectious diseases. The modular nature of the TriKE platform enables rapid development of new molecules targeting diverse antigens, supporting strategic combination therapies and expansion into multiple oncology indications. Founded in 2015 with technology originally licensed from the National Institutes of Health, GT Biopharma is headquartered in Tempe, Arizona, and conducts research and development operations in the United States. The company collaborates with leading academic institutions and global clinical sites to advance its pipeline. Under the leadership of President and CEO Scott K. Koenig, GT Biopharma continues to pursue its mission of delivering next-generation cell-engaging therapies to improve outcomes for patients with cancer and beyond.View GT Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings PepsiCo (10/9/2025)Fastenal (10/13/2025)Wells Fargo & Company (10/14/2025)Citigroup (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)The Goldman Sachs Group (10/14/2025)BlackRock (10/14/2025)ASML (10/15/2025)Kinder Morgan (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
